Clinical Research Directory

Inclusion Criteria: 1. Subject is male or female age 22 or older 2. Diagnosed with elevated blood pressure or hypertension and verified during Visit #1 by standardized seated cuff SBP 3. Have not taken antihypertensive medication for ≥30 days prior to the SEPV 4. Subject is expected to have sufficient vision, hearing, and hand strength (hand strength is demonstrated by a maximum voluntary contraction (MVC) equaling 35 units of force in both hands measured by a dynamometer 5. Subject has baseline BP measurements collected and completes study device training during Baseline Assessment (Visit #1); 6. Subject agrees to maintain non-use of medications and over-the-counter (OTC) supplement regimen related to hypertension throughout the treatment phase; 7. Patient can comply with and agrees to complete all required study procedures, study clinic visits, and associated activities; 8. Patient must be able to understand and give written informed consent in the language provided; 9. Subject must have SBP of 130 to ≤149 mmHg, if subjects present with SBP reading of ≥140mmHg they will receive heightened monitoring throughout the first month of the study Exclusion Criteria: 1. Subject is a female of childbearing potential (e.g., not postmenopausal for at least one year or has not had a hysterectomy or tubal ligation) not using medically effective birth control (e.g., hormonal methods in use at least 30 days prior to screening or barrier methods such as condom and spermicide in use at least 14 days prior to visit 1) or is pregnant, lactating, or plans to become pregnant during the study). 2. BP ≥150 mmHg (systolic) and/or \>90 mmHg (diastolic) 3. A history of heart failure with current New York Heart Association (NYHA) class III- IV functional classification 4. Currently has, or has had a history, of atrial fibrillation, in accordance with 2007 Heart Rhythm Society (HRS)/European Heart Rhythm Association (EHRA)/European Cardiac Arrhythmia Society (ECAS) guidelines 5. Patient has experienced hospitalization due to a hypertensive emergency, with impending or progressive target organ dysfunction (i.e., renal dysfunction, left ventricular hypertrophy or CNS involvement) within the past six (6) months 6. A \>10 mmHg difference in seated cuff SBP between the right and left arms collected during the SEPV; 7. Unstable BP, defined as \>5 mmHg variance between any two (2) consecutive weekly readings (with a maximum of four (4) attempts) to determine a baseline BP measurement ; 8. Arm circumference greater than 45 cm; 9. Acute illness, infection, or inflammation 10. Presence of any unstable cardiovascular disorder, such as MI, unstable angina, significant arrhythmia, stroke, or TIA; within the last six (6) months, or other serious comorbidity that would be likely to impact life expectancy to less than one (1) year or limit patient cooperation or study compliance; 11. A history of rest or exertional angina pectoris in the previous six (6) months; 12. History of solid organ transplant 13. Any secondary form of hypertension (HTN) etiology, including but not limited to primary aldosteronism, chronic steroid therapy and Cushing syndrome, pheochromocytoma, aorta coarctation or untreated thyroid or parathyroid disease; 14. Concurrent participation in an investigational clinical study that has not completed the follow-up period or planned participation in another study within the next six (6) months; 15. Patient has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete, good quality data or the completion of the research study; 16. Patients who currently own or have owned another Zona Plus device and are, or have been, voluntarily performing the isometric handgrip activities. 17. Subject plans for greater than 10% of body weight loss/gain (10% of body weight over a 6-month period) during the study